Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM49IGF)

• Drug Name: Pefloxacin Drug Info
• Synonyms: Abactal; Labocton; PERFLOXACIN; PFLX; Peflacine; Pefloxacine; Pefloxacino; Pefloxacinum; Pefloxacin methanesulfonate; Silver Pefloxacin; AM-725; EU-5306; Pefloxacin [INN-French]; Pefloxacino [INN-Spanish]; Pefloxacinum [INN-Latin]; Pefloxacin (USAN/INN); Pefloxacin [USAN:BAN:INN]; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo

Indication

Disease Entry	ICD 11	Status	REF
Gonococcal urethritis	1A70.0Y	Approved	[1]

• Therapeutic Class: Antiinfective Agents
• Cross-matching ID:
  PubChem CID: 51081
  ChEBI ID: CHEMBL267648
  CAS Number: CAS 70458-92-3
  TTD Drug ID: DM49IGF

Molecule-Related Drug Atlas

Drug(s) Targeting DNA topoisomerase II (TOP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[4]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[5]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[6]
Idarubicin	DMM0XGL	Acute myelogenous leukaemia	2A41	Approved	[4]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[4]
Lomefloxacin	DMVRH9C	Bacterial infection	1A00-1C4Z	Approved	[7]
Dexrazoxane	DMD7X1O	Breast cancer	2C60-2C65	Approved	[4]
Podofilox	DMT2EJP	Condyloma	1A95	Approved	[8]
Enoxacin	DMYTE6L	Acute gonococcal cervicitis		Approved	[2]

Drug(s) Affected By Cytochrome c (CYCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[9]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[10]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[11]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[12]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[13]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[14]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[15]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[16]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[17]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] Drug information of Pefloxacin, 2008. eduDrugs.
• [2] Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
• [3] Under ambient UVA exposure, pefloxacin exhibits both immunomodulatory and genotoxic effects via multiple mechanisms. J Photochem Photobiol B. 2018 Jan;178:593-605. doi: 10.1016/j.jphotobiol.2017.12.014. Epub 2017 Dec 15.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
• [6] Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
• [7] Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
• [8] Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
• [9] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [10] Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
• [11] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [12] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [13] K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro. 2012 Apr;26(3):429-34. doi: 10.1016/j.tiv.2012.01.013. Epub 2012 Jan 17.
• [14] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [15] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [16] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [17] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [18] [Role of Bcl-xL in the cathepsin D-associated apoptosis of K562 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Jun;13(3):379-82.